🟢 Haemonetics is trading 6.2% up in after-hours trading after CSL Plasma supply agreement

Haemonetics is trading 6.2% up at $114.90 after investors continued reacting to its non-exclusive CSL Plasma supply agreement.

• The agreement allows CSL to deploy NexSys PCS devices with Persona PLUS technology and purchase related U.S. disposables; it has no minimum purchase commitments and does not yet change fiscal 2027 guidance.
• Haemonetics gained 15.93% on August 18, when the agreement was disclosed, suggesting continued enthusiasm over renewed plasma-platform demand.